Âé¶¹´«Ã½Ó³»­

Âé¶¹´«Ã½Ó³»­

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Baseline characteristics of LRRK2 G2019S carriers in the Virtual Assessment of LRRK2 carriers to Optimize Research in Parkinson’s Disease (VALOR-PD) study
Movement Disorders
Movement Disorders Posters (7:00 AM-5:00 PM)
088

To describe the baseline characteristics of a national virtual cohort of LRRK2 G2019S carriers with and without self-reported Parkinson’s disease (PD) recruited from a personal genomics company.

LRRK2 mutations are among the most common causes of genetic PD, and LRRK2 is a promising target for the development of disease-modifying therapeutics for PD.  Traditional, site-based research presents barriers to recruitment of a sufficiently sized genetic sub-population. Collaboration with a personal genomics company may broaden the reach of research, and virtual, video-based visits can reduce participation barriers, enabling recruitment and engagement of a geographically diverse cohort.

LRRK2 G2019S carriers with and without self-reported PD were recruited through a personal genomics company. This 36-month virtual, observational, single-site study is engaging and characterizing participants through annual video-based visits. Annual visits include standard patient- and clinician- reported outcome measures (modified for remote assessment) that assess motor, cognitive, psychiatric, and sleep domains.

Over 60 weeks, 335 individuals were pre-screened, and 277 individuals from 34 states enrolled in the study. Of those enrolled, 59 have self-reported PD (mean (SD) age 68.6 (8.4), 98% white, 53% female, 80% Ashkenazi Jewish, modified MDS-UPDRS part III score 22.0 (10.8), 37.3% MoCA score ≤26), and 215 do not have self-reported PD (mean (SD) age 54.0 (15.1), 96% white, 59% female, 73% Ashkenazi Jewish, modified MDS-UPDRS part III score 1.8 (4.5), 25.1% MoCA score ≤26). Of our participants, 68% are novel research participants, and 94% would participate in a clinical trial for the prevention of PD.

Enrollment of a national virtual cohort of LRRK2 carriers through a single site has been successful. VALOR-PD (NINDS P50NS108676) has rapidly recruited and characterized novel research participants interested in future clinical trial participation. The study stands to develop a virtual model of research that broadens recruitment potential, lowers barriers to participation, and engages new participants.

Authors/Disclosures
Ruth Schneider, MD, FÂé¶¹´«Ã½Ó³»­ (University of Rochester)
PRESENTER
Dr. Schneider has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Escape Bio. The institution of Dr. Schneider has received research support from The Michael J. Fox Foundation. The institution of Dr. Schneider has received research support from NIH. The institution of Dr. Schneider has received research support from Acadia Pharmaceuticals. The institution of Dr. Schneider has received research support from CHDI. The institution of Dr. Schneider has received research support from Biohaven Pharmaceuticals. The institution of Dr. Schneider has received research support from Parkinson Study Group. The institution of Dr. Schneider has received research support from The Michael J. Fox Foundation. The institution of Dr. Schneider has received research support from Bial. Dr. Schneider has received personal compensation in the range of $500-$4,999 for serving as a Telemedicine Evaluator with Parkinson's Foundation.
Stella Jensen-Roberts Ms. Jensen-Roberts has nothing to disclose.
No disclosure on file
Julia M. Soto, MPH (Center for Health and Technology, University of Rochester Medical Center) Julia Soto has nothing to disclose.
Meghan E. Pawlik, MS (Center for Health + Technology) Miss Pawlik has nothing to disclose.
No disclosure on file
Katherine D. Amodeo, MD (Westchester Medical Center) The institution of Dr. Amodeo has received research support from Roche. The institution of Dr. Amodeo has received research support from EIP Pharma. The institution of Dr. Amodeo has received research support from Acadia. The institution of Dr. Amodeo has received research support from MJFF. The institution of Dr. Amodeo has received research support from NINDS.
Saloni Sharma, MBBS Dr. Sharma has nothing to disclose.
Blanca Y. Valdovinos, MD (University of Rochester) Dr. Valdovinos has nothing to disclose.
Roy Alcalay, MD (Columbia University) Dr. Alcalay has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Genzyme/Sanofi. Dr. Alcalay has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biogen. Dr. Alcalay has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Gain Therapeutics. Dr. Alcalay has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Vanqua Bio. Dr. Alcalay has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Takeda. Dr. Alcalay has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biohaven. Dr. Alcalay has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Capsida. Dr. Alcalay has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Servier. The institution of Dr. Alcalay has received research support from Michael J. Fox Foundation. The institution of Dr. Alcalay has received research support from Parkinson's Foundation. The institution of Dr. Alcalay has received research support from Silverstein Foundation. Dr. Alcalay has received personal compensation in the range of $50,000-$99,999 for serving as a Consultant with Parkinson's Foundation.
Robert G. Holloway, MD, MPH, FÂé¶¹´«Ã½Ó³»­ (University of Rochester Medical Center) Dr. Holloway has nothing to disclose.